Induced Pluripotent Stem Cell (iPSC) Market Report 2026

Induced Pluripotent Stem Cell (iPSC) Market Overview

• Induced Pluripotent Stem Cell (iPSC) market size has reached to $3.67 billion in 2025 • Expected to grow to $5.75 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Neurological Disorder Prevalence Fuels Growth Of The Induced Pluripotent Stem Cell Market • Market Trend: Collaborative Advances In Induced Pluripotent Stem Cell (iPSC) Technology Enhancing Regenerative Medicine And Personalized Therapeutic Solutions • North America was the largest region in 2025 and Western Europe is the fastest growing region.

What Is Covered Under Induced Pluripotent Stem Cell (iPSC) Market?

Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes, and neurons. This process involves introducing specific genes that induce the cell to become pluripotent, meaning it can differentiate into any cell type in the body (e.g., heart, brain, liver cells). The main derived cell types of induced pluripotent cells are hepatocytes, fibroblasts, keratinocytes, amniotic cells, and others. Hepatocytes are the liver's primary functional cells, performing a staggering array of metabolic, endocrine, and secretory tasks. The various applications include academic research, drug development, and discovery, toxicity screening, and regenerative medicine and are used in several sectors such as hospitals, and research laboratories.

What Is The Induced Pluripotent Stem Cell (iPSC) Market Growth Forecast?

The induced pluripotent stem cell (ipsc) market size is expected to see strong growth in the next few years. It will grow to $5.75 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to expansion of regenerative medicine applications, increasing demand for personalized therapies, growing investment in cell and gene therapy, rising adoption of ipscs in neurological and cardiac research, favorable regulatory support for advanced therapies. Major trends in the forecast period include growing use of ipscs in disease modeling, increasing adoption in drug discovery and toxicity testing, expansion of patient-specific cell line development, rising focus on ethical alternatives to embryonic stem cells, advancements in reprogramming efficiency and cell stability.

Global Induced Pluripotent Stem Cell (iPSC) Market Segmentation

1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types 2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy 3) By End-User: Hospitals, Research Laboratories Subsegments: 1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing, Disease Modeling And Regenerative Therapies 2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair, Fibroblast-Based Disease Research 3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research, Skin Regeneration Therapies 4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research, Amniotic Fluid-Based Regenerative Applications 5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling, Cardiomyocytes For Heart Disease Studies, Endothelial Cells For Vascular Research

What Is The Driver Of The Induced Pluripotent Stem Cell (iPSC) Market?

The increasing prevalence of neurological disorders is expected to propel the growth of the induced pluripotent stem cell market going forward. Neurological disorder refers to a medical condition that affects the nervous system, including the brain, spinal cord, and nerves. Common neurological disorders include acute spinal cord injury, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and more. Pluripotent stem cells offer the potential for studying disease mechanisms and drug testing, providing insights into neurological disorders' causes, and aiding in the development of regenerative therapies for conditions such as Parkinson's and Alzheimer's disease. For instance, in October 2023, according to the World Federation of Neurology (WFN), a UK-based international nonprofit neurological organization, more than 40% of the global population were living with a neurological condition, and the overall neurological disease burden was projected to nearly double by 2050. Therefore, the increasing prevalence of neurological disorders is driving the growth of the induced pluripotent stem cell market.

Key Players In The Global Induced Pluripotent Stem Cell (iPSC) Market

Major companies operating in the induced pluripotent stem cell (ipsc) market are FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, Parexel, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart

Global Induced Pluripotent Stem Cell (iPSC) Market Trends and Insights

Major companies operating in the induced pluripotent stem cell (IPSC) market are collaborating to Advance iPSC Technology to enhance regenerative medicine applications, improve disease modeling, accelerate drug discovery, and develop personalized therapeutic solutions. Induced Pluripotent Stem Cell (iPSC) technology refers to the scientific process and methodologies used to reprogram adult somatic cells (such as skin or blood cells) back into a pluripotent state, making them capable of differentiating into any type of cell in the body. For instance, in April 2024, SCG Cell Therapy Pte Ltd, a Singapore-based biotechnology company, and the Agency for Science, Technology and Research, a Singapore-based Statutory board, launched joint laboratories aimed at advancing cellular immunotherapies. The initiative is supported by close to S$30 million, emphasizing Singapore's commitment to advancing biotechnology and healthcare solutions. The collaboration aims to develop scalable manufacturing processes for GMP-grade iPSC products, addressing the challenges of translating laboratory innovations into clinically viable therapies.

What Are Latest Mergers And Acquisitions In The Induced Pluripotent Stem Cell (iPSC) Market?

In May 2024, Theragent Inc., a US-based biotechnology company, partnered with Pluristyx Inc. With this partnership, Theragent aims to expand its portfolio by incorporating Pluristyx's expertise in providing induced Pluripotent Stem Cell (iPSC) products. Pluristyx Inc. is a US-based biotechnology company that offers induced pluripotent stem cell (iPSC) products.

Regional Outlook

North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2025. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Induced Pluripotent Stem Cell (iPSC) Market?

The induced pluripotent stem cell (IPSC) market consists of sales of induced pluripotent stem cells and related services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Induced Pluripotent Stem Cell (iPSC) Market Report 2026?

The induced pluripotent stem cell (ipsc) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the induced pluripotent stem cell (ipsc) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.